Replies to post #308141 on Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

.IPIX will bring ABSSI over the top... IPIX will run with it.

Probably not.

Here is a great article on the topic:

https://sperotherapeutics.com/billion-dollar-antibiotics-era-stewardship/

It's from 2018 and it lists ABSSSI as an antibiotic space that has low unmet need and high competition in the space.

Note they remark that one of the great attributes of success (granted to Cubicin in the article) was that of a high unmet need and a lack of generic competition. ABSSSI was a blue sky for Cubicin. Now that Cubicin is generic, there is no longer a high unmet need (Cubicin/Dapto meets it) and Daptomycin is now generic. It appears the very comparison Leo was chasing after doomed Brilacidin's profitability in the ABSSSI space.

We developed a star product in 2014 for a market that disappeared in 2016 with Cubicin's patent expiration.

The only thing that can bring that market back is for antibiotic resistance to Daptomycin to become a major problem. Until then, no one is investing $30M in a B-ABSSSI phase 3 barring a government incentive.

Go IPIX!